Table II.
Genetic alteration for three specimens obtained from the patient over the study period.
| Gene | Specimen from 2009 | Specimen from 2013 | Specimen from 2015 |
|---|---|---|---|
| EGFR (L858R) | 11% | 25% | 78% |
| RB1 (Y567fs) | 6% | 20% | 57% |
| TP53 (S241C) | 20% | 34% | 73% |
| PIK3CA (E545A) | No | No | 3% |
| MYCL amplification | No | No | 21.6 times |
| RB1 loss | No | Yes | Yes |
| RAC1 amplification | 2.7 times | No | No |
Percentages refer to the percentage of cells positive for the mutation. EGFR, epidermal growth factor receptor; RB, retinoblastoma; PIK3CA, phosphatidylinositol-3-kinase catalytic α; TP53, tumor protein p53; MYCL, MYCL proto-oncogene, bHLH transcription factor; RAC1, ras-related C3 botulinum toxin substrate 1 (ρ family, small GTP binding protein Rac1).